Explore how immune time-resolved Förster resonance energy transfer (iFRET) offers new insights into predicting immunotherapy ...
Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...